mesh cube/iStock via Getty Images Investment Overview Axsome Therapeutics, Inc. ( AXSM ), the commercial-stage Pharma company whose >$9bn market cap valuation (at the time of writing) is mostly derived from a diverse and intriguing pipeline, reported its Q4 and full-year 2025 earnings and business updates earlier today, February 23rd. Firstly, let's consider the financials - shared in the table be...
mesh cube/iStock via Getty Images Investment Overview Axsome Therapeutics, Inc. ( AXSM ), the commercial-stage Pharma company whose >$9bn market cap valuation (at the time of writing) is mostly derived from a diverse and intriguing pipeline, reported its Q4 and full-year 2025 earnings and business updates earlier today, February 23rd. Firstly, let's consider the financials - shared in the table below (source: Axsome earnings presentation , released today): Axsome Q4 FY25 financial summary (presentation) The year-on-year uplift in revenues - 65% in Q4, to $196m, and 66% in full-year 2025, to $638.5m is undeniably impressive, with sales of Auvelity - a combination of dextromethorphan and bupropion, first approved in August 2022 to treat Major Depressive Disorder ("MDD") in adults, particularly impressive. Sunosi, a novel oral dopamine and norepinephrine reuptake inhibitor (DNRI), trace amine-associated receptor 1 (TAAR1) agonist, and 5-HT1A agonist, acquired from Jazz Pharmaceuticals plc ( JAZZ ) in 2022, approved in the U.S. and Europe to treat Excessive Daytime Sleepiness ("EDS") in adult patients with narcolepsy or obstructive sleep apnea ("OSA"), also showed solid revenue growth, while Symbravo (meloxicam-rizatriptan), a novel, oral, selective COX-2 inhibitor and 5-HT1B/1D agonist, approved in January last year to treat migraine, appears to have gotten off to a slow start commercially. In terms of profit/loss, Axsome states in its earnings press release : Net loss was $28.6 million, or $(0.56) per share, for the fourth quarter 2025 and $183.2 million, or $(3.68) per share, for the full year 2025, compared to a net loss of $74.9 million, or $(1.54) per share, for the fourth quarter 2024 and $287.2 million, or $(5.99) per share, for the full year 2024. Axsome remains loss-making, but less so than in 2024, albeit more than in 2023, 2022, or 2021. Cash and equivalents were reported as $322.9m as of the end of Q4, and a "face-value" debt position was reported of $190m....